Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences Fund (JFNSX)

74.76 +0.79 (+1.07%)
At close: 8:00 PM EDT

Top 10 Holdings (42.01% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 8.92%
UNH
UnitedHealth Group Incorporated 6.72%
NOVO-B.CO
Novo Nordisk A/S 5.33%
AZN.L
AstraZeneca PLC 4.00%
ABBV
AbbVie Inc. 3.61%
AMGN
Amgen Inc. 3.20%
MRK
Merck & Co., Inc. 2.79%
SAN.PA
Sanofi 2.63%
BSX
Boston Scientific Corporation 2.46%
NVS
Novartis AG 2.34%

Sector Weightings

Overall Portfolio Composition (%)

Cash 0.49%
Stocks 98.79%
Bonds 0.01%
Others 0.42%
Preferred 0.26%
Convertible 0.03%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JFNSX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.18 5.28
Price/Sales 0.35 2.06
Price/Cashflow 0.04 17.54
Median Market Cap 86,861.57 34,862.81
3 Year Earnings Growth 3.96 32.48

Bond Holdings

Performance & Risk

YTD Return 12.43%
5y Average Return 11.87%
Rank in Category (ytd) 12
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.74
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.73B
YTD Return 16.29%
Yield 0.00%
Morningstar Rating
Inception Date Dec 31, 1998

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers